As of September 19, 2023, Cantor Fitzgerald analyst Jennifer Kim has once again expressed her positive outlook on Insmed (NASDAQ: INSM) by reiterating an Overweight rating for the company. Additionally, she has maintained a price target of $46.
Interline: Kim’s reaffirmation of the Overweight rating signifies her belief in the company’s potential for growth and success in the market. By maintaining a price target of $46, she suggests that Insmed’s stock has the potential to reach this level in the foreseeable future.
This analysis from Cantor Fitzgerald highlights the confidence placed in Insmed’s performance and prospects by industry experts. It showcases the ongoing interest and positive sentiment surrounding the company within the investment community as of September 19, 2023.
Updated on: 28/09/2023
Debt to equity ratio: Strong Buy
Price to earnings ratio: Strong Sell
Price to book ratio: Strong Buy
DCF: Strong Buy
ROE: Strong Sell
We did not find social sentiment data for this stock
|Analyst / firm||Rating|
INSM Stock Performance on September 19, 2023: Stable Day in the Stock Market with Promising Growth Prospects
INSM Stock Performance on September 19, 2023:
On September 19, 2023, Insmed Incorporated (INSM) experienced a relatively stable day in the stock market. Let’s dive into the details of INSM’s performance.
INSM’s previous close on September 18, 2023, was $26.55. The stock opened slightly lower the next day at $26.38. Throughout the trading day, INSM’s stock price fluctuated within a range of $26.21 to $26.54.
The trading volume for INSM on September 19, 2023, was 825 shares. In comparison, the average trading volume over the past three months stood at 1,200,599 shares.
INSM has a market capitalization of $3.8 billion.
Examining INSM’s earnings growth, we see that the company experienced a decline in earnings over the past year. The earnings growth rate for the previous year stood at -0.95%. However, the company is projected to rebound, with estimated earnings growth of +33.50% over the next five years.
INSM’s revenue growth for the previous year was +30.19%.
When evaluating INSM’s valuation metrics, we observe that the price-to-earnings (P/E) ratio is listed as NM. However, the price-to-sales ratio is 10.02, and the price-to-book ratio is 40.97.
Looking ahead, INSM’s next reporting date is scheduled for November 1, 2023. The earnings per share (EPS) forecast for the current quarter is -$1.11.
In terms of INSM’s financials, the company reported annual revenue of $245.4 million for the previous year. However, it posted a net loss of -$481.5 million, resulting in a net profit margin of -196.26%.
INSM operates in the Health Technology sector and falls under the Pharmaceuticals: Major industry. The company’s corporate headquarters are located in Bridgewater, New Jersey.
Investors should consider the company’s financials, growth prospects, and industry dynamics before making any investment decisions. Conducting thorough research and consulting with a financial advisor is recommended to make informed investment choices.
Insmed Inc Shows Strong Growth Potential with Median Target Price of $41.50: Analysts Recommend Buying Stock
Insmed Inc, a biopharmaceutical company, reached a median target price of $41.50 on September 19, 2023, representing a 57.26% increase from the last price. Analysts have provided a 12-month price forecast, with a high estimate of $52.00 and a low estimate of $33.00, indicating a positive outlook. Twelve polled investment analysts recommend buying stock in Insmed Inc, reflecting confidence in the company’s potential for growth. The company’s financial performance for the current quarter shows an earnings per share of -$1.11 and sales of $76.0 million. Insmed Inc’s financial results will be reported on November 1, providing further information on its performance. Investors should conduct further research and consider industry trends before making investment decisions.